Payment overview · 2025
General Payments
$49.84
2 reported records · 2 companies
Healthcare provider profile · identity verified
Scott Phillip Bloom
Allopathic & Osteopathic Physicians|Family Medicine · JERICHO, NY · NPI 1457432171
Verified facts
What the public records show
CMS Open Payments records show Scott Phillip Bloom received $49.84 in general payments during 2025 across 2 reported records.
ABBVIE INC. accounted for 60.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.14 | 60.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.70 | 39.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $49.84 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $30.14 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.14 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1013 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 732 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 635 | 80 |
| Furosemide | Furosemide | 575 | 85 |
| Donepezil Hcl | Donepezil Hcl | 431 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 431 | 75 |
| Eliquis | Apixaban | 348 | 61 |
| Pantoprazole Sodium | Pantoprazole Sodium | 338 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 323 | 54 |
| Gabapentin | Gabapentin | 299 | 50 |
| Potassium Chloride | Potassium Chloride | 280 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 268 | 40 |
| Losartan Potassium | Losartan Potassium | 266 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 247 | 41 |
| Famotidine | Famotidine | 236 | 38 |
| Mirtazapine | Mirtazapine | 236 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 233 | 34 |
| Omeprazole | Omeprazole | 220 | 34 |
| Simvastatin | Simvastatin | 211 | 27 |
| Metformin Hcl | Metformin Hcl | 207 | 39 |
| Valsartan | Valsartan | 201 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 32 |
| Trazodone Hcl | Trazodone Hcl | 168 | 29 |
| Sertraline Hcl | Sertraline Hcl | 164 | 26 |
| Memantine Hcl | Memantine Hcl | 147 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 144 | 29 |
| Lisinopril | Lisinopril | 142 | 18 |
| Glimepiride | Glimepiride | 134 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 25 |
| Finasteride | Finasteride | 129 | 21 |
| Montelukast Sodium | Montelukast Sodium | 124 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 123 | 16 |
| Carvedilol | Carvedilol | 114 | 20 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 112 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 91 | 69 |
| Tramadol Hcl | Tramadol Hcl | 90 | 24 |
| Xarelto | Rivaroxaban | 88 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 87 | 12 |
| Torsemide | Torsemide | 86 | 17 |
| Atenolol | Atenolol | 76 | 11 |
| Ezetimibe | Ezetimibe | 73 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 71 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 12 |
| Myrbetriq | Mirabegron | 69 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 68 | 40 |
| Alprazolam | Alprazolam | 67 | 15 |
| Bupropion Xl | Bupropion Hcl | 64 | 12 |
| Spironolactone | Spironolactone | 63 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 56 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 56 | 12 |
| Allopurinol | Allopurinol | 55 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 54 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 11 |
| Ramipril | Ramipril | 52 | 13 |
| Folic Acid | Folic Acid | 48 | suppressed |
| Anastrozole | Anastrozole | 47 | suppressed |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Prednisone | Prednisone | 46 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 39 |
| Memantine Hcl Er | Memantine Hcl | 44 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 44 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 41 | suppressed |
| Jardiance | Empagliflozin | 41 | suppressed |
| Sucralfate | Sucralfate | 41 | suppressed |
| Irbesartan | Irbesartan | 40 | suppressed |
| Ketoconazole | Ketoconazole | 40 | 27 |
| Midodrine Hcl | Midodrine Hcl | 40 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Meloxicam | Meloxicam | 35 | suppressed |
| Digoxin | Digoxin | 34 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 34 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Loperamide | Loperamide Hcl | 33 | 18 |
| Cephalexin | Cephalexin | 32 | 18 |
| Budesonide | Budesonide | 31 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 31 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 28 | 11 |
| Rivastigmine | Rivastigmine Tartrate | 28 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 27 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Tobramycin | Tobramycin | 23 | 13 |
| Brilinta | Ticagrelor | 22 | suppressed |
| Clonazepam | Clonazepam | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Rivastigmine | Rivastigmine | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 12 |
| Albuterol Sulfate | Albuterol Sulfate | 20 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 20 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Nyamyc | Nystatin | 20 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Mirabegron Er | Mirabegron | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Generlac | Lactulose | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 12 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Hydroxyurea | Hydroxyurea | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Prevalite | Cholestyramine | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $49.84 · 2 records | ABBVIE INC. | JARDIANCE, QULIPTA, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error